Project Grant R41TR003255

This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the engineering of improved uricase enzyme variants for treating gout. The $298,915 award to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business in Seattle, WA, aims to develop uricase variants with enhanced stability, reduced immunogenicity, and extended...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $318,457 to Drexel University for research to develop a zwitterionic polyethylene glycol (ZPEG) polymer as a replacement for traditional polyethylene glycol (PEG) in therapeutic delivery. The research aims to 1) synthesize and characterize ZPEG with different structures to understand how it enhances blood circulation of modified...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $396,750 to the University of Pittsburgh to conduct a mechanistic study on PEG-asparaginase-induced liver injury. The research aims to: Demonstrate that inhibition of ATGL-mediated white adipose tissue lipolysis can attenuate PEG-asparaginase-induced liver injury. Show that...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,921 to Ubiquitx Inc., a New York-based biotechnology company, to develop a therapeutic platform for upregulating antigen presentation to enhance immune surveillance of diseased cells. The award supports the development and characterization of Ubiquitinase Chimeric Ligands for Induced Proximity (UbiClips)...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $147,656 to The Trustees of Columbia University to integrate biomaterials and genomic tools for glycan-based programming of immune cells. The research aims to develop self-assembling modular hydrogels that can programmably display glycan ligands to initiate maturation...

This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...

This $800,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a longer-acting version of the novel anti-cancer biologic drug L-asparaginase (EBD-300). The goal is to expand the use of this enzyme therapy beyond its current application in pediatric acute lymphoblastic leukemia (ALL) to also treat adult ALL patients and other cancer types. The awarded work will engineer and evaluate EBD-300 variants with improved in vivo persistence,...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Cornell University a $435,412 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The goal of this 2-year project is to develop a biomaterial-driven, immunosuppressive platform that enables the re-administration of engineered adeno-associated virus (AAV) gene delivery vectors while maintaining their transduction efficiency....

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal grant program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286), provides funding of $481,438 to the University of California, San Diego (UCSD) to develop a novel therapeutic delivery system called "Cargocytes." Cargocytes are derived from mesenchymal stem cells that have been genetically engineered to...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the interaction between biodegradable microparticles comprised of the biomaterial acetalated dextran (Ace-Dex) and B cells. The $501,011 award to the University of North Carolina at Chapel Hill, with a performance period from November 2024 to October 2029, will support three specific research...